IS DARATUMUMAB ELIMINATED IN THE URINE OF PATIENTS WITH AL AMYLOIDOSIS?

被引：0
|
作者：
Gil Alos, D. [1 ]
Cuevas Gomez, D. [2 ]
Colmenares Gil, R. [1 ]
Gil Manso, R. [1 ]
Iniguez Garcia, R. [1 ]
Zamanillo Herrero, I [1 ]
Poza Santaella, M. [1 ]
Puerta Fonolla, P. [2 ]
Sanchez Pina, J. M. [1 ]
Martinez Lopez, J. [1 ]
机构：
[1] Hosp 12 Octubre, Serv Hematol & Hemoterapia, Madrid, Spain
[2] Hosp 12 Octubre, Serv Bioquim & Anal Clin, Madrid, Spain
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-030
引用
下载
收藏
页码：150 / 150
页数：1
相关论文
共 50 条
  • [31] Occurrence of prostaglandin D synthase in urine of patients with immunoglobulin light chain amyloidosis (AL amyloidosis)
    Murphy, C
    Niewold, T
    Solomon, A
    PROSTAGLANDINS, 1996, 51 (04): : 291 - 291
  • [32] Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapy
    Theodorakakou, Foteini
    Fotiou, Despina
    Spiliopoulou, Vasiliki
    Roussou, Maria
    Malandrakis, Panagiotis
    Ntanasis-Stathopoulos, Ioannis
    Migkou, Magdalini
    Eleutherakis-Papaiakovou, Evangelos
    Kanellias, Nikolaos
    Papanikolaou, Asimina
    Gavriatopoulou, Maria
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    Kastritis, Efstathios
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (03) : 411 - 415
  • [33] Predictive Factors of Overall Survival in Patients with Relapsed AL Amyloidosis Treated with Single Agent Daratumumab
    Szalat, Raphael
    Gustine, Joshua
    Sloan, John Mark
    Sanchorawala, Vaishali
    BLOOD, 2021, 138
  • [34] IMMUNOGLOBULIN LIGHT CHAIN FRAGMENTS IN THE SERUM AND URINE OF PATIENTS WITH AL AMYLOIDOSIS
    MERLINI, GP
    MASTANDUNO, M
    MOY, PW
    OSSERMAN, EF
    CLINICAL RESEARCH, 1985, 33 (02): : A559 - A559
  • [35] Amyloidosis: the use of the Daratumumab
    Anzai, Adriano
    Utino, Armelin
    Katayama, Haroldo
    Spir, Ighor A. Z.
    Lemos, Marcio A.
    Anhesini, Mauricio
    Tiezzi, Oswaldo S.
    Spir, Patricia R. N.
    Otani, Pericles
    Bernardo, Wanderley M.
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2020, 66 (12): : 1620 - 1620
  • [36] Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC)
    Levin, Daniel
    Lewis, Ellen
    McCulloch, Sylvia
    Lee, Holly
    Tay, Jason
    Duggan, Peter
    Neri, Paola
    Bahlis, Nizar
    Jimenez-Zepeda, Victor H.
    LEUKEMIA & LYMPHOMA, 2024, 65 (03) : 403 - 406
  • [37] Management and outcomes of advanced stage cardiac AL amyloidosis in the daratumumab era
    Feuvrier-Rivera, Ariana
    Kumar, Anupama Deepa
    Urey, Marcus Anthony
    Costello, Caitlin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Responses to salvage therapy in AL amyloidosis after progression on daratumumab.
    Mann, Hashim
    Salei, Yana
    Fogaren, Teresa
    Toskic, Denis
    Scalia, Stephanie
    Ma, Xun
    Zhou, Ping
    Comenzo, Ray
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Efficacy and Tolerability of Daratumumab in Heavily Pretreated AL Amyloidosis: A Systematic Review
    Rahman, Muhammad Aadil
    Khan, Ali Younas
    Ijaz, Awais
    Tariq, Muhammad Junaid
    Usman, Muhammad
    Khalil, Muhammad Jahanzeb
    Fraz, Muhammad Asad
    Jamil, Faiza
    Rafae, Abdul
    Malik, Mustafa Nadeem
    Selene, Insija Ilyas
    Jose, Jemin Aby
    Safdar, Ahmad
    McBride, Ali
    Anwer, Faiz
    BLOOD, 2018, 132
  • [40] Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden
    Schwotzer, Rahel
    Manz, Markus Gabriel
    Pederiva, Stefanie
    Waibel, Christine
    Caspar, Clemens
    Lerch, Erika
    Flammer, Andreas J.
    Brouwers, Sofie
    Seeger, Harald
    Heimgartner, Raphael
    Fehr, Thomas
    Rossi, Davide
    Bianchi, Elena
    Stussi, Georg
    Ghilardi, Guido
    Gerber, Bernhard
    HEMATOLOGICAL ONCOLOGY, 2019, 37 (05) : 595 - 600
12345